Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer
Ultra Structure of Peritoneum at Electronic Microscopy in Control Subjects and Patients With Gastric Cancer
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Region Metropolitana
-
Santiago, Region Metropolitana, Chile
- Department of Surgery, Clinical Hospital, University of Chile
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients with operable local gastric adenocarcinoma
Exclusion Criteria:
- previous abdominal surgery
- previous open or blunt abdominal trauma
- history of inflammatory bowel disease or Typhoid Fever, Gallstone disease, chemotherapy or radiotherapy, or any other abdominal condition that could alter peritoneal integrity.
- All other gastric malignancies such as lymphomas, GIST, carcinoids
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Gastric cancer
patients with operable local gastric adenocarcinoma were studied
|
|
Control group
patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Patricio Burdiles, MD, Department of Surgery, Clinical Hospital, University of Chile
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OAIC 043/02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomach Neoplasm
-
NCT01758965CompletedMalignant Neoplasm of Stomach | Benign Neoplasm of Stomach
-
NCT03563326RecruitingMetastases, Neoplasm | Neoplasm Seeding | Neoplasm, Stomach
-
NCT02845908CompletedMalignant Neoplasm of Stomach Stage IV
-
NCT02697838UnknownClinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric CancerMalignant Neoplasm of Stomach Stage II
-
NCT01910974CompletedStomach Neoplasm | Rectal Neoplasm | Intestinal Neoplasm
-
NCT02205047CompletedMalignant Neoplasm of Stomach | Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Epidermal Growth Factor Receptor (EGFR) Protein Overexpression
-
NCT05880667RecruitingMalignant Neoplasm of Stomach | Neoplasm - Soft Tissue Pelvis Malignant Secondary
-
NCT00144378CompletedNeoplasm Metastasis | Stomach Neoplasm
-
NCT07333820Not yet recruitingMalignant Neoplasm of Stomach, Unspecified
-
NCT06033976RecruitingNeoplasm, Colorectal | Neoplasm, Stomach | Neoplasm, Esophagus | Neoplasm, Duodenal